Background
Phase III, open-label RCT. 268 patients with newly diagnosed PMBCL aged 18–60. First randomized trial directly comparing DA-EPOCH-R versus R-CHOP in PMBCL, addressing whether the NCI single-arm DA-EPOCH-R results were superior to R-CHOP in a head-to-head comparison.
Interventions and follow up
Arm A: DA-EPOCH-R × 6 cycles — etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin (doses adjusted per nadir counts) + rituximab 375mg/m²; consolidation RT at investigator discretion
Arm B: R-CHOP × 6 cycles — rituximab 375mg/m² + cyclophosphamide 750mg/m² + doxorubicin 50mg/m² + vincristine 1.4mg/m² + prednisone 40mg/m²; consolidation RT at investigator discretion
Primary endpoint: Progression-free survival
Median follow-up: 60.8 months
Arm B: R-CHOP × 6 cycles — rituximab 375mg/m² + cyclophosphamide 750mg/m² + doxorubicin 50mg/m² + vincristine 1.4mg/m² + prednisone 40mg/m²; consolidation RT at investigator discretion
Primary endpoint: Progression-free survival
Median follow-up: 60.8 months
Results
5-year PFS: 82.8% vs 70.4%, HR 0.52, 95% CI 0.30–0.90, P=.019
5-year OS: 89.8% vs 82.9%, HR 0.59, 95% CI 0.31–1.14, P=.116 — not significant
CR rate (end of treatment): 79.0% vs 65.0%
Consolidation RT use: 11.5% vs 35.3%
5-year OS: 89.8% vs 82.9%, HR 0.59, 95% CI 0.31–1.14, P=.116 — not significant
CR rate (end of treatment): 79.0% vs 65.0%
Consolidation RT use: 11.5% vs 35.3%
Adverse events
Hematologic (grade ≥3, DA-EPOCH-R vs R-CHOP): Neutropenia 66.4% vs 36.9%; febrile neutropenia 37.3% vs 12.3%; anemia 19.4% vs 6.2%.
Other: R-CHOP arm had more consolidation RT-related late effects (not separately quantified); treatment-related deaths 2 vs 1.
Other: R-CHOP arm had more consolidation RT-related late effects (not separately quantified); treatment-related deaths 2 vs 1.
Conclusions
DA-EPOCH-R significantly improved 5-year PFS over R-CHOP (82.8% vs 70.4%, HR 0.52) in PMBCL, with substantially less need for consolidation radiotherapy, confirming DA-EPOCH-R as the preferred frontline regimen for eligible patients.
Key Limitations
OS benefit did not reach statistical significance (HR 0.59, P=.116) — may reflect post-progression salvage options and immature data. Significantly higher acute toxicity with DA-EPOCH-R, particularly febrile neutropenia (37% vs 12%), limiting use without robust supportive care infrastructure. RT policy was not strictly mandated, introducing heterogeneity. Applicable primarily to patients ≤60 years without severe comorbidities.
Clinical Context
IELSG37 provides the randomized evidence that DA-EPOCH-R is superior to R-CHOP in PMBCL, confirming the prior NCI single-arm signal. ASCO and ESMO guidance support DA-EPOCH-R as a preferred frontline option for eligible patients, with R-CHOP retained for elderly or frail patients. An ongoing question is the role of PET-guided RT in DA-EPOCH-R-treated patients with residual FDG-avidity.